MILSTEIN  ZHANG  &  WU  LLC

Dr. Zhang is a co-founder, Chairman and co-Managing Principal at Milstein Zhang & Wu LLC. 

Dr. Zhang has extensive experience representing pharmaceutical, biotechnology, clean technology, advanced materials, medical devices, and scientific instruments companies, including advising clients on IP strategies, product patent clearance, licensing and patent preparation and prosecution. Dr. Zhang also helps clients with IP issues in R&D collaborations, venture funding, M&A and other transactions. Dr. Zhang regularly advises Asia-based clients with regard to various legal issues.

Prior Legal Experience

• Cooley Godward Kronish LLP, Special Counsel 
• Ensemble Therapeutics Corp.,    Chief IP Counsel
• Genzyme Corporation,         Patent Counsel
• Testa Hurwitz & Thibeault LLP, Patent attorney

Representative Publications

• "Maximizing the commercial value of personalized therapeutics and companion diagnostics" Nature Biotechnology, vol. 31, 803-805 (2013).

• "Around the Block" Nature Biotechnology, vol. 28, 1239-1241 (2010).

• "Navigating Pharmacogenomics Patenting" GEN, July 2009.

• "IP Strategies for Chinese Biotech and Pharmaceutical Companies" Trend in Bio/Pharma Indus. No.5, 2009.

• "Patent Strategies for Personalized Medicine" Mass. High Tech.: J. of New Engl. Tech., Jan. 23, 2009.

• "Enforcing Pharmaceutical and Biotech Patent Rights in China" Nature Biotechnology vol. 26, 1235-1240 (2008).

• "The Shifting Landscape of Declaratory Judgment Law" IP Law360, July 3, 2008.

• "ITC Section 337 IP Infringement Investigations" China Patent Agency, J. of All-China Patent Agents Association, No. 2, 2008.

• "Trends and Legislative Activities in Follow-on Biologics" Progress in Pharma. Sci. No. 3, 2008.

• "Ready for Prime Time in the U.S.? - An Overview of the Regulatory and Patent Environment for Follow-on Biologics" Trend in Bio/Pharma. Indus., No. 3, 2007.

• "Year of the Patent -- Patent Protection in China," IEEE Spectrum, January 2003.

• "Bush Proposal May Facilitate Generic Drug Entry," IP Observer, Spring 2003.

• "Perfluorobarrelene" Tetrahedron Letters 2008, vol. 49, 52, 7349-7351.

• "Octafluorobicyclo[2.2.0]hex-1(4)-ene: A Greatly Strained Alkene with Novel Reactivity" J. Amer. Chem. Soc., 1996, 39, 9454.

• "Photooxidation of Diimine Dithiolate Pt(II) Complexes Induced by Charge Transfer to Diimine Excitation", Inorg. Chem. 1996, 36, 7102.

• "Carbon-Carbon Bond Fragmentation in Aminoalcohol Radical Cations. Kinetics, Thermodynamics Correlations and Mechanism", J. Am. Chem. Soc. 1996, 118, 5655.

Recent Presentations

• “IP/Patent Considerations in Generic Drug Development” 2015 Shanghai Int'l BIO-FORUM, Shanghai, China, June 9, 2015.

• "Passion and Commitment: Drivers for Entrepreneurship Success" 2015 SAPA-CT Annual Conference, Yale University, New Heaven, Connecticut, March 22, 2015.

• "IP/Patent and Legal Considerationsfor Personalized Medicines" 1st Chaoyang Int'l Conference of Medicine, Beijing, China, Dec. 21, 2014.

• “Catch the China Wave: Understanding China's IPR Landscape” Licensing Executives Society (US & Canada) 2014 Mid-Year Meeting, New York, March 27, 2014.

• “IP Strategies for Personalized Medicines” 2013 Shanghai Int'l BIO-FORUM, Shanghai, China, May 30, 2013.

• “Innovation and Patents:  Securing the Chinese Market ” 3^rd U.S.-China Pharma Conference, Harvard Medical School, Boston, Massachusetts, May 21, 2013.

• “Patent Considerations for Developing BioSimilar and BioBetter Drugs” Biosimilar & FOB China 2012, Shanghai, China, October 24, 2012.

• “IP/Legal Aspects of International Biopharma R&D Collaborations” 2012 Shanghai Int'l BIO-FORUM, Shanghai, China, May 10, 2012.

• “The Faculty Entrepreneur: How does a Professor Start a Company?” 2011 Bridge Medical Summit, Cambridge, Massachusetts, November 19, 2011.

• "Interface of FDA Regulatory Framework and Patent Law", Conference of Overseas Chinese Entrepreneurs, Wuhan, China, June 28, 2011.

• "Patent Strategies for Medical Device and Diagnostic Companies", Medical Device & Diagnostic Industries (MDDI) Conference, IBM Innovation Center, Waltham, MA, Dec. 4, 2010.

• "IP Strategies for Chinese Biotech and Pharmaceutical Companies", Shanghai Int'l BIO-FORUM, Shanghai, China, Nov. 10, 2010.

• "Nanotechnology and IP", Nanotechnology in the Health & Applied Sciences:  Implications for Researchers and Librarians, U. Mass. Amherst, May 24, 2010

• "Is IP still an issue for drug R&D in China?"  Drug R&D in China - Status, Opportunity, International Collaboration and Challenges, Northeastern Section of American Chemical Society (NESACS), Woburn, MA, May 22, 2010

• "Overview of the Interface of U.S. Antitrust and Patent Laws", U. Mass. Boston, Nov. 19, 2009

• "Outsourcing R&D to China:  IP Considerations", Webinar series: U.S. Department of Commerce Office of China Economic Area Presents, July 28, 2009

• "Interface of FDA Regulatory Framework & Patent Law", Newton, MA, Aug. 23, 2009

• "IP Strategies for Chinese Biotechnology and Pharmaceutical Companies", MIT, April 11, 2009

• "IP Strategies for Realizing Commercial Value of Nanotechnology Research", SUNY, College of Nanoscale Science and Engineering, Nov.  7, 2008

Education

• Vanderbilt University Law School, JD, 1999
• Dartmouth College, PhD, Organic Chemistry, 1995
• University of Science and Technology of China, BS, Chemistry, 1986

Contact Information

Tel.  (617) 529-8369

 Email   philip.zhang@mzwiplaw.com